Galectin Therapeutics Inc. 2022 Form 10-K Summary
Business context and reporting period
Galectin Therapeutics is a clinical-stage biopharmaceutical company developing galectin-targeting therapies for fibrotic disease and cancer. The lead candidate is belapectin (GR-MD-02), an intravenous galectin-3 inhibitor being evaluated primarily for NASH cirrhosis and prevention of esophageal varices. The filing covers the fiscal year ended December 31, 2022, with comparative results for 2021.
- No products have been approved for sale and the Company has generated no revenue since inception.
- The NAVIGATE adaptive Phase 2b/3 trial enrolled 357 patients; the final patient was randomized in February 2023.
- As of February 2023, the Company had 59,443,682 common shares outstanding and 12 full-time employees.
Financial performance and liquidity
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $31.7 million | $23.8 million | Up 33% |
| General and administrative expense | $6.6 million | $6.4 million | Up 4% |
| Total operating expenses | $38.4 million | $30.2 million | Up 27% |
| Net loss | $38.8 million | $30.5 million | Loss increased 27% |
| Net loss applicable to common stockholders | $38.9 million | $30.7 million | Loss increased 27% |
| Basic and diluted loss per share | $0.65 | $0.52 | Higher loss per share |
| Net cash used in operations | $31.1 million | $24.3 million | Use increased $6.7 million |
| Cash and cash equivalents at year-end | $18.6 million | $39.6 million | Down $21.1 million |
The Company reported no operating margin because it has no revenue; its operating loss was $38.4 million. Interest expense and debt-discount amortization increased to $1.0 million from $0.5 million, partly offset by a $0.6 million favorable change in derivative liabilities.
- Net cash provided by financing activities was $10.0 million in 2022, consisting primarily of borrowings under a related-party convertible line of credit.
- Total liabilities were $53.5 million at December 31, 2022, including approximately $30.0 million of related-party convertible notes and $9.9 million drawn under the related-party line of credit.
- The July 2022 line of credit permits borrowings of up to $60 million through July 31, 2024; $10 million had been drawn by year-end.
- Accumulated deficit was $309.6 million, and stockholders’ equity was negative $33.9 million.
Material changes versus the prior comparable period
- Research and development spending increased $7.9 million, primarily due to NAVIGATE trial activities, clinical supplies, manufacturing, toxicity studies and increased research personnel.
- Cash used in operations increased 28%, while year-end cash declined 53% because operating cash usage exceeded financing proceeds.
- The Company entered into a $60 million unsecured convertible line of credit with Chairman Richard E. Uihlein and drew $10 million during 2022. The arrangement also includes warrants to purchase up to 1.7 million common shares.
- Common shares outstanding increased modestly to 59.4 million from 59.3 million. In addition, the Company had 11.6 million warrants, 5.7 million options and securities convertible into additional common shares outstanding or issuable.
- Management identified a material weakness related to a computational error in a research and development accrual during 2022. Additional reviews and documentation were implemented, and management concluded the weakness was remediated by year-end.
Guidance, outlook, commentary and risks
- Management believes available cash and the related-party credit facility are sufficient to fund currently planned operations through at least December 31, 2024. Additional financing will be required thereafter, and there is no assurance that financing will be available on acceptable terms.
- Management expected topline results from the NAVIGATE interim analysis in fall 2024. The trial is designed to select a dose and potentially re-estimate sample size or terminate for efficacy or futility.
- A Phase 2 oncology trial in recurrent or metastatic head and neck cancer may begin depending on financing.
- The Company remains dependent on belapectin, successful clinical trials, regulatory approvals, third-party manufacturers and contract research organizations.
- Prior studies provide supportive findings but also important limitations: NASH-CX did not meet its primary endpoint in the total population, and NASH-FX did not meet its primary endpoint.
- COVID-19 previously delayed site activation and enrollment, particularly in Europe, and supply-chain, regulatory, site and patient-enrollment disruptions could recur.
- Potential dilution is significant from convertible debt, warrants, options, preferred stock, deferred stock units and potential future equity financing.
- Related-party financing creates reliance on Chairman Richard E. Uihlein, who also has significant voting and economic ownership. The Company has no commercial products, no revenue base and has incurred losses in every year since inception.
- The audit identified going concern, derivative-liability valuation and accrued clinical-trial expenses as critical audit matters. The financial statements received an unqualified audit opinion, but the auditor did not express an opinion on internal control effectiveness.
Most important facts for investors to verify
- Current NAVIGATE enrollment, interim-analysis timing, efficacy, safety and dose-selection results.
- Remaining availability and terms of the $60 million related-party line of credit, including conversion terms, interest and warrant dilution.
- Actual cash burn and whether $18.6 million of year-end cash plus available credit remains sufficient through December 2024.
- Outstanding convertible securities, warrants and options and their potential effect on ownership and voting power.
- Resolution and sustainability of the remediation of the research and development accrual material weakness.
- Regulatory status of belapectin, including the absence of any FDA marketing approval and the requirements for future Phase 3 development.
- Financing requirements and timing for the proposed oncology trial and continued NAVIGATE operations.